Extract
We thank S. Yamamoto and co-workers for their letter, in which they argue that sputum colour assessment and sputum characterisation should include assessment of haemoptysis. Our study showed that the use of a four-point sputum colour chart to assess patients in stable state, which has been validated in bronchiectasis, could predict clinically relevant outcomes such as exacerbations and severe exacerbations [1].
Shareable abstract
Haemoptysis is an important symptom but not part of the assessment of sputum colour in stable patients https://bit.ly/4d67Stm
Footnotes
Conflict of interest: S. Aliberti reports grants or contracts from Insmed Incorporated, Chiesi, Fisher and Paykel, and GSK, royalties or licences from McGraw Hill, consulting fees from Insmed Incorporated, Insmed Italy, Insmed Ireland Ltd, Zambon Spa, AstraZeneca UK Ltd, AstraZeneca Pharmaceutical LP, CSL Behring GmbH, Grifols, Fondazione internazionale Menarini, Moderna, Chiesi, MCD Italis SrL, Brahms, Physioassist SAS and GlaxoSmithKline Spa, payment or honoraria for lectures, presentations, manuscript writing or educational events from GlaxoSmithKline Spa, Thermofisher Scientific, Insmed Italy, Insmed Ireland, Zambon and Fondazione Internazionale Menarini, and participation on a data safety monitoring board or advisory board with Insmed Incorporated, Insmed Italy, AstraZeneca UK Ltd and MSD Italia Srl. J.D. Chalmers reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Genentech, Gilead Sciences, GlaxoSmithKline, Grifols, Insmed, LifeArc and Novartis, and consulting fees from AstraZeneca, Chiesi, GlaxoSmithKline, Insmed, Grifols, Novartis, Boehringer Ingelheim, Pfizer, Janssen, Antabio and Zambon.
- Received July 18, 2024.
- Accepted July 20, 2024.
- Copyright ©The authors 2024. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
